Partial Transfer of CURED Shares and Exclusion from Equity-Method Accounting
First written in FY2023-Q3. 1 of 3 entries say "Achieved", first in FY2023. Latest entry: FY2024-Q1.
14 other companies' latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「As the impact of the equity-method investment losses of affiliates, which had materially affected profit or loss in the previous fiscal year, was limited, among other factors, the respective figures turned profitable, rising from an ordinary loss of ¥54.731 million in the previous year to ordinary profit of ¥13.517 million.」
In the first quarter following the partial transfer of CURED shares and its removal from the equity-method scope, the impact of equity-method investment losses, which had materially affected the previous fiscal year, became limited. - FY2023AchievedAnnual report
「This was also positive, resulting in an inflow of funds, due in part to proceeds of ¥77.787 million from the sale of shares in an affiliate.」
The partial transfer of CURED shares was executed and ¥77.787 million was received. CURED was removed from the equity-method affiliates. - FY2023-Q3First statedAnnual report
「Our board of directors resolved to transfer part of the shares of CURED Co., Ltd. (the “CURED company”), an equity-method affiliate. As a result, the CURED company will be removed from our equity-method affiliates.」
The board resolution and agreement were completed on 6 February 2023, and the planned transfer of 12,500 CURED shares would reduce the ownership interest from 22.48% to 19.90%, removing CURED from the equity-method affiliates. The share transfer was scheduled to be executed in March 2023.